Kenneth Harrap

Last updated

Professor

Kenneth Harrap

CBE CChem FRSC
Born
Kenneth Reginald Harrap

(1931-11-20)20 November 1931
Died9 February 2017(2017-02-09) (aged 85)
Nationality United Kingdom
Occupation Oncological biochemist
Employer Institute of Cancer Research

Professor Kenneth Reginald Harrap CBE CChem FRSC (1931-2017) was a British oncological biochemist.

Contents

Early life and education

Harrap was born in Streatham, London, on 20 November 1931. [1] [2] He was educated at Woking Grammar School and George Green's School, London. [2]

He graduated with a BSc in Chemistry from the University of London, then worked for a while as an analytical chemist at Hopkins & Williams. [1]

In 1964 He spent a sabbatical period as a visiting fellow at the Children's Cancer Research Foundation in Boston, United States. [1]

He received a DSc in Pharmacology and Biochemistry from London University in 1977. [3]

Career

The early part of his career was directed at identifying biochemical abnormalities of cancer cells. [4] [5]

In 1956 he moved to the Institute of Cancer Research's Chester Beatty Research Institute in London. [1] [6] He was promoted to Head of the Department of Applied Biochemistry in 1970, Head of the Department of Biochemical Pharmacology in 1977, Chairman of the Drug Development Section in 1982, and Director of the CRC's Centre for Cancer Therapeutics in 1994. [6]

Harrap chaired the British Association for Cancer Research from 1987 to 1990. [1]

He was elected a Fellow of the Royal Society of Chemistry, and received the American Association for Cancer Research's Bruce F. Cain award and the Barnett Rosenberg Award, both in 1995. [1] He was made a Commander of the Order of the British Empire (CBE) in the 1998 New Year Honours, "for services to cancer research". [7]

He is credited with the discovery of Carboplatin, JM 216 (Satraplatin), and AMD 473. [3]

Platinum based anti-cancer agents

A collaboration with Johnson Matthey established by Professor Tom Connors was expanded into an extensive search for an effective but less toxic therapy to replace Cisplatin. [1]

JM8 was identified and successfully launched as Carboplatin (Paraplatin) by Bristol Myers Squibb in 1986. [8] [9] This achievement was recognized in 1991 with the Queens Award for Technological Achievement, awarded jointly to the Drug Development Section at the Institute of Cancer Research, of which Harrap was Head, to the Royal Marsden Hospital, and to Johnson. [10]

Antimetabolite anticancer drugs

Harrap's interest in antimetabolites as cancer drugs led to a collaboration with AstraZeneca on the development of thymidylate synthase inhibitors. Raltitrexed was developed and launched as Tomudex. [11]

Building on the work done by Harrap's group, thymidylate synthase has continued to be a target of interest for the development of anti cancer drugs. One of these, BGC 945, has been taken into clinical trial at the Royal Marsden, and licensed to Carrick for further clinical development. [12]

Retirement

Harrap became emeritus professor of pharmacology at the University of London, a distinguished emeritus fellow of the Cancer Research Campaign, and an associate and visiting scientist at the Institute of Cancer Research on his retirement in 1997. [1] [6] He was profiled as the "Cover Legend" in volume 58, issue 21 (November 1998) of the journal Cancer Research , which featured his portrait photograph on its front page and described him as "one of Britain's top leaders in the field of cancer chemotherapy". [3]

Harrap joined his wife Dr. Beverley Weston to form Weston and Harrap Consulting, advising start up and small biotech companies on cancer drug development and commercial potential. [1]

He died on 9 February 2017. [1] He was survived by his wife, two daughters, and grandchildren. [13] `

The University of London's Harrap Chair of Pharmacology and Therapeutics is endowed in his honour. [13] A blue plaque commemorating the work of the Institute for Cancer Research, including the discovery of Carboplatin, was erected by the Royal Society of Chemistry in 2018. Beverley Weston was one of the speakers at the event. [14]

Related Research Articles

<span class="mw-page-title-main">UCL School of Pharmacy</span>

The UCL School of Pharmacy is the pharmacy school of University College London (UCL). The School forms part of UCL's Faculty of Life Sciences and is located in London, United Kingdom.

The Institute of Cancer Research is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.

<span class="mw-page-title-main">Thymidine kinase</span> Enzyme found in most living cells

Thymidine kinase is an enzyme, a phosphotransferase : 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC 2.7.1.21. It can be found in most living cells. It is present in two forms in mammalian cells, TK1 and TK2. Certain viruses also have genetic information for expression of viral thymidine kinases. Thymidine kinase catalyzes the reaction:

<span class="mw-page-title-main">Carboplatin</span> Medication used to treat cancer

Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid; thus, competitive inhibition can occur, and the presence of antimetabolites can have toxic effects on cells, such as halting cell growth and cell division, so these compounds are used as chemotherapy for cancer.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.

<span class="mw-page-title-main">Thromboxane-A synthase</span> Mammalian protein found in Homo sapiens

Thromboxane A synthase 1 , also known as TBXAS1, is a cytochrome P450 enzyme that, in humans, is encoded by the TBXAS1 gene.

<span class="mw-page-title-main">Thymidylate synthase</span> Enzyme

Thymidylate synthase (TS) is an enzyme that catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Thymidine is one of the nucleotides in DNA. With inhibition of TS, an imbalance of deoxynucleotides and increased levels of dUMP arise. Both cause DNA damage.

<span class="mw-page-title-main">Bernard Beryl Brodie</span> American biochemist

Bernard Beryl Brodie was a founding scientist in the area of biochemical and neurochemical pharmacology whose work in the 1940s and 1950s had great impact. He was a major figure in the fields of drug metabolism and drug therapy, studying how the absorption and interactions of drugs in the body. Brodie helped to found and lead the Laboratory of Chemical Pharmacology at the National Heart Institute in Bethesda, Maryland, one of the National Institutes of Health. He was a member of the United States National Academy of Sciences.

<span class="mw-page-title-main">Laurence Pearl</span>

Laurence Harris Pearl FRS FMedSci is a British biochemist and structural biologist who is currently Professor of Structural Biology in the Genome Damage and Stability Centre and was Head of the School of Life Sciences at the University of Sussex.

<span class="mw-page-title-main">Paul Workman (scientist)</span> British oncologist (born 1952)

Paul Workman is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology. He is President and CEO of The Institute of Cancer Research In London.

<span class="mw-page-title-main">Shankar Balasubramanian</span> Indian-born British chemist

Sir Shankar Balasubramanian is an Indian-born British chemist and Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry at the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College, Cambridge. He is recognised for his contributions in the field of nucleic acids. He is scientific founder of Solexa and Cambridge Epigenetix.

<span class="mw-page-title-main">William A. Haseltine</span> American biologist (born 1944)

William A. Haseltine is an American scientist, businessman, author, and philanthropist. He is known for his groundbreaking work on HIV/AIDS and the human genome.

<span class="mw-page-title-main">Ian A. Graham</span> British biologist (born 1963)

Ian Alexander Graham is a professor of Biochemical Genetics in the Centre for Novel Agricultural Products (CNAP) at the University of York.

<span class="mw-page-title-main">Mark A. Lemmon</span> English biochemist (born 1964)

Mark Andrew Lemmon an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute.

<span class="mw-page-title-main">Nigel Scrutton</span>

Nigel Shaun Scrutton is a British biochemist and biotechnology innovator known for his work on enzyme catalysis, biophysics and synthetic biology. He is Director of the UK Future Biomanufacturing Research Hub, Director of the Fine and Speciality Chemicals Synthetic Biology Research Centre (SYNBIOCHEM), and Co-founder, Director and Chief Scientific Officer of the 'fuels-from-biology' company C3 Biotechnologies Ltd. He is Professor of Enzymology and Biophysical Chemistry in the Department of Chemistry at the University of Manchester. He is former Director of the Manchester Institute of Biotechnology (MIB).

<span class="mw-page-title-main">ONX-0801</span> Chemical compound

ONX-0801 is an experimental drug that has been developed to target ovarian cancer. It is a folate receptor alpha mediated thymidylate synthase inhibitor.

Yeshwant S. Bakhle, is a British pharmacologist.

<span class="mw-page-title-main">Rajendra Kumar Sharma</span>

Rajendra Kumar Sharma is a professor at the Department of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine. He holds an earned Doctor of Science from the University of Saskatchewan, and was elected a Fellow of the Royal Society of the Arts (FRSA) in 2014. His contributions to research have been documented in the Encyclopedia of Saskatchewan – A Living Legacy. Sharma has made several discoveries in the areas of colorectal cancer and the cardiovascular system.

References

  1. 1 2 3 4 5 6 7 8 9 10 "The Drug Discoverer - A pioneer of cancer drug discovery – Professor Ken Harrap 1931–2017 - The Institute of Cancer Research, London". Institute of Cancer Research . Retrieved 26 June 2017.
  2. 1 2 Jackson, Bob; Newell, Herbie (30 March 2017). "Ken Harrap obituary". The Guardian.
  3. 1 2 3 Weinhouse, sydney (November 1998). "Cover Legend" (PDF). Cancer Research (58): [unnumbered front matter page].
  4. ↑ Harrap, K. R. (1965). "Some Aspects of Sulphydryl Metabolism in Granulocytic Leukemia". European Journal of Cancer . 1 (3–4): 189–194. doi:10.1016/0014-2964(65)90047-2. PMID   5226523.
  5. ↑ Harrap, K.R.; Jackson, R.C. (1969). "Some Biochemical Aspects of Leukemias. Leukocyte Glutathione Metabolism in Chronic Granulocytic Leukemias". European Journal of Cancer. 5 (5): 61–67. doi:10.1016/0014-2964(69)90090-5. PMID   5252516.
  6. 1 2 3 Daphne Christie; Tilli Tansey, eds. (2007). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN   978-0-85484-112-7. OL   25554713M. Wikidata   Q29581749.
  7. ↑ "No. 54993". The London Gazette (Supplement). 30 December 1997. p. 9.
  8. ↑ "Carboplatin: Chemistry for Fighting Cancer". Johnson Matthey.[ dead link ]
  9. ↑ "Scientific Symposium on Paraplatin" (PDF). Platinum metals review. Archived from the original (PDF) on 3 November 2016. Retrieved 12 October 2011.
  10. ↑ "No. 52509". The London Gazette (Supplement). 19 April 1991. p. 4.
  11. ↑ Jackman, Ann L.; Boyle, F. Thomas; Harrap, Kenneth R. (February 1996). "Tomudex TM (ZD1694): from concept to care, a programme in rational drug discovery". Investigational New Drugs. 14 (3): 305–308. doi:10.1007/BF00194534. PMID   8958186.
  12. ↑ Jamala, A. (November 2010). "Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs". Mini-Reviews in Medicinal Chemistry . 10 (13): 1211–1222. doi:10.2174/13895575110091211. PMID   20854257.
  13. 1 2 Workman, Paul (15 February 2017). "The Drug Discoverer - A pioneer of cancer drug discovery – Professor Ken Harrap 1931–2017". The Institute of Cancer Research. Retrieved 8 January 2020.
  14. ↑ "Blue Plaque for the Institute for Cancer Research". Royal Society of Chemistry . Retrieved 8 January 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.